因子XIa抑制剂Asundexian根据基线梗死模式对MRI隐匿性梗死结局的影响
PACIFIC-Stroke 2期随机试验的事后探索性分析,纳入1808例轻中度非心源性缺血性卒中患者,评估Asundexian(10、20或50 mg每日一次)对比安慰剂对复发性卒中和隐匿性梗死的影响。结果显示,Asundexian 50 mg组复发性缺血性卒中或新发隐匿性梗死的风险有降低趋势(HR 0.71,95%CI 0.45-1.11),复发性缺血性卒中或TIA风险也有降低趋势(HR 0.59,95%CI 0.33-1.06),但在单个小皮质下梗死患者中未见此效果;新发皮质隐匿性梗死的粗发生率比为0.56(95%CI 0.28-1.12),差异无统计学意义。结论提示Asundexian可能预防新发栓塞性梗死而非小动脉闭塞,此假设需未来试验验证。
要点
- Asundexian 50 mg每日一次组复发性缺血性卒中或新发隐匿性梗死的风险较安慰剂组有降低趋势,HR 0.71(95%CI 0.45-1.11)。
- 单个小皮质下梗死患者中,Asundexian 50 mg组复发性缺血性卒中或隐匿性梗死的HR为1.14(95%CI 0.62-2.10),未见获益。
- Asundexian 50 mg组新发皮质隐匿性梗死的粗发生率比为0.56(95%CI 0.28-1.12),差异未达统计学显著。
核心结论
- 探索性、未经证实的结果提示Asundexian可能预防新发栓塞性梗死,但不预防小动脉闭塞。
- 隐匿性脑梗死亚型对 anticoagulant 预防反应不同的假设应在未来试验中检验。
研究设计与样本
- PACIFIC-Stroke 2期随机试验的事后探索性分析,纳入1808例轻至中度非心源性缺血性卒中患者,随机分配至Asundexian(10、20或50 mg每日一次)或安慰剂,均联合抗血小板治疗。
- 要求随机化后72小时内完成脑MRI,并在26周或研究药物停用时复查。
主要发现
- 1808例随机患者中,1780例(98.5%)基线MRI可判读,其中1628例(91.5%)有至少1个弥散加权成像阳性的急性梗死灶。
- 1439例患者获得MRI随访,其中1358例在试验期间无有症状卒中。
- 与安慰剂相比,Asundexian 50 mg每日一次组复发性缺血性卒中或新发隐匿性梗死的风险有降低趋势(HR 0.71,95%CI 0.45-1.11)。
- Asundexian 50 mg每日一次组复发性缺血性卒中或TIA(次要结局)的风险有降低趋势(HR 0.59,95%CI 0.33-1.06)。
- 在单个小皮质下梗死患者中,Asundexian 50 mg组复发性缺血性卒中或隐匿性梗死的HR为1.14(95%CI 0.62-2.10),复发性缺血性卒中或TIA的HR为0.93(95%CI 0.28-3.06)。
局限性
- 结果为探索性、未经证实的。
- 作者指出,隐匿性脑梗死亚型对 anticoagulant 预防反应不同的假设应在未来试验中检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Exploratory analysis of the phase 2 PACIFIC-Stroke (Program of Anticoagulation via Inhibition of FXIa by the Oral Compound BAY 2433334-Non-Cardioembolic Stroke) randomized trial suggested that asundexian, an oral factor XIa inhibitor, prevents recurrent stroke and transient ischemic attacks in patients with atherosclerotic stroke. In this post hoc exploratory analysis, we hypothesized that asundexian would be more effective in patients enrolled with large, multiple, or cortical acute infarcts on magnetic resonance imaging than in patients enrolled with a single small subcortical acute infarct, and asundexian would prevent incident cortical covert infarcts. METHODS: In this placebo-controlled double-blinded randomized controlled trial, patients with mild-to-moderate noncardioembolic ischemic stroke were assigned to asundexian (10, 20, or 50 mg once daily) or placebo, in addition to antiplatelet therapy. Brain magnetic resonance imagings were required within 72 hours of randomization and repeated at 26 weeks or at discontinuation of the study drug. RESULTS: Of 1808 randomized patients, 1780 (98.5%) had interpretable baseline magnetic resonance imagings, of which 1628 (91.5%) had ≥1 diffusion-weighted imaging positive acute infarcts. Magnetic resonance imaging follow-up was obtained in 1439 patients, of whom 1358 had no symptomatic stroke during the trial period. Compared with placebo, asundexian 50 mg daily conferred a trend toward reduced risk of recurrent ischemic stroke or incident covert infarcts (hazard ratio, 0.71 [95% CI, 0.45-1.11]) and recurrent ischemic stroke or transient ischemic attack (secondary outcome; hazard ratio, 0.59 [95% CI, 0.33-1.06]) that was not evident in patients with single small subcortical infarcts (hazard ratios, 1.14 [95% CI, 0.62-2.10] and 0.93 [95% CI, 0.28-3.06]). Incident cortical covert infarcts were reduced in patients taking asundexian 50 mg, but the difference was not statistically significant (crude incidence ratio, 0.56 [95% CI, 0.28-1.12]). CONCLUSIONS: These exploratory, unconfirmed results suggest that asundexian may prevent new embolic infarcts but not small artery occlusion. The hypothesis that subtypes of covert brain infarcts respond differently to anticoagulant prevention should be tested in future trials. REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT04304508.
引用
- Smith EE, Shoamanesh A, Xu L, et al. Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes. Stroke. 2024. PMID: 38174569. doi:10.1161/STROKEAHA.123.043198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。